In this video interview with SOHO Insider Al-Ola A. Abdallah, MD, associate professor and director of the Plasma Cell Disorder program at the University of Kansas Medical Center, discusses the DREAMM-7 phase 3 trial results for belantamab mafodotin plus bortezomib and dexamethasone (BVd) versus daratumumab plus bortezomib and dexamethasone (DVd) in relapsed multiple myeloma.
Dr. Abdallah also addressed the earlier FDA advisory committee “no” recommendation in July 2025 due to safety and dosing concerns. “They didn’t vote against the efficacy of the treatment. They actually acknowledged the fact that the treatment has been fairly effective,” Dr. Abdallah said.
